Literature DB >> 8170433

Flucloxacillin and cholestatic hepatitis.

H Jick, L E Derby, A D Dean, D A Henry.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8170433

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  7 in total

Review 1.  Communication of medical product risk: how effective is effective enough?

Authors:  Stephen A Goldman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

Authors:  Stefan Russmann; James A Kaye; Susan S Jick; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

3.  Updated study on risk of cholestatic liver disease and flucloxacillin.

Authors:  Lin Li; Hershel Jick; Susan S Jick
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 4.  Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?

Authors:  B M Devereaux; D H Crawford; P Purcell; L W Powell; H P Roeser
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.

Authors:  Lise Aagaard; Ebba Holme Hansen
Journal:  BMC Clin Pharmacol       Date:  2009-03-03

6.  Optimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injury.

Authors:  Kevin Wing; Krishnan Bhaskaran; Liam Smeeth; Tjeerd P van Staa; Olaf H Klungel; Robert F Reynolds; Ian Douglas
Journal:  BMJ Open       Date:  2016-09-02       Impact factor: 2.692

7.  Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.

Authors:  Kevin Wing; Krishnan Bhaskaran; Louise Pealing; Adrian Root; Liam Smeeth; Tjeerd P van Staa; Olaf H Klungel; Robert F Reynolds; Ian Douglas
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.